AFFILIATIONS
1 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy
2 Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy
3 Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy
4 Department of Molecular Biotechnology and Health Sciences, University of Torino, and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
5 Department of Molecular Biotechnology and Health Sciences, University of Torino, and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
6 Divisione di Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
7 Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine (DIMI), University of Verona, Verona, Italy
8 Hematology and Stem Cell Transplantation Unit, Ospedale San Francesco, Nuoro, Italy
9 Division of Hematology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
10 Division of Hematology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
11 Division of Hematology, Hospital Saints Antonio, Biagio and Cesare Arrigo, Alessandria, Italy
12 Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico Armando Businco, ARNAS G. Brotzu, Cagliari, Italy
13 Facility of Epidemiology and Biostatistics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
14 Hematology Section, Cosenza Hospital, Cosenza, Italy
15 Division of Hematology, Università degli Studi del Piemonte Orientale, Novara, Italy
16 Clinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy
17 Clinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy
18 Dipartimento di Scienze di Laboratorio ed Ematologiche, Area Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
19 Dipartimento di Scienze di Laboratorio ed Ematologiche, Area Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
20 Dipartimento di Scienze di Laboratorio ed Ematologiche, Area Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
21 Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy
22 Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy
23 Clinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, Aviano, Italy
24 Division of Hematology, Università degli Studi del Piemonte Orientale, Novara, Italy
25 Hematology Section, Cosenza Hospital, Cosenza, Italy
26 Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine (DIMI), University of Verona, Verona, Italy
27 Haematology and Medical Oncology, AORN Sant'Anna e San Sebastiano, Caserta, Italy
28 Hematology Unit, Department of Medicine, University of Padova, Padova, Italy
29 Hematology Unit, ARNAS Garibaldi, Catania, Italy
30 Hematology, Department of Oncology, AOU Careggi, Firenze, Italy
31 Divisione di Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
32 Department of Molecular Biotechnology and Health Sciences, University of Torino, and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy, Department of Molecular Biotechnology and Health Sciences, University of Torino, and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
33 Dipartimento di Scienze di Laboratorio ed Ematologiche, Area Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
ABSTRACT
Background: Covalent Bruton's tyrosine kinase inhibitors (cBTKi) are now standard frontline treatment for chronic lymphocytic leukemia (CLL). All three agents (ibrutinib, acalabrutinib, zanubrutinib) interrupt B-cell receptor signaling and downregulate CXCR4 surface expression, weakening the adhesion of leukemic cells to lymphoid tissue and mobilizing them into the bloodstream. This produces, in the majority of cases, a transient, expected rise in absolute lymphocyte count (ALC), known as redistribution lymphocytosis, before it gradually declines. Although this phenomenon is well described for ibrutinib, a direct, real-life comparison of lymphocytosis kinetics across all three approved cBTKi, and of the clinico-biological features that shape it, has been lacking.
Methods: We conducted a multicenter, retrospective, real-life study across 16 Italian centers, including 368 patients with CLL who started frontline cBTKi monotherapy at standard doses (ibrutinib, n=114; acalabrutinib, n=130; zanubrutinib, n=124). ALC was recorded at baseline and at 1-2 weeks and 1, 2, 3, 6, 9, and 12 months, and expressed at each timepoint as a ratio to the baseline value. Between-arm comparisons at each timepoint used non-parametric tests with Bonferroni correction.
Results: Baseline characteristics were similar across arms: median age was 72 years (interquartile range: 66-78y); 67.1% (247/368) of patients had splenomegaly, 34.2% (126/368) had nodal bulk ≥5 cm, 31.5% (116/368) had mutated IGHV and 37.1% (134/368) had del(17p) and/or TP53 disruption. Across the cohort, ALC rose to 1.5- to 1.7-fold the baseline value within the first 1-2 weeks in all three arms, with an apparent higher ALC for acalabrutinib over ibrutinib and zanubrutinib. ALC then declined steadily, falling below baseline by month 2-3 and to 9%-15% of baseline by month 12. On adjusted pairwise comparison, at timepoint-specific analysis, ALC was higher for ibrutinib compared to acalabrutinib at 3 months (p=0.016), at 6 months (p=0.050), and 9 months (p=0.010); at this latter timepoint there was a difference also between ibrutinib and zanubrutinib (p=0,047).
Different trajectories for the 3 drugs were observed according to IGHV stratified analysis. Among the mutated IGHV patients, curves diverged from month 2-3 onward, with acalabrutinib lymphocytosis diminishing faster than ibrutinib or zanubrutinib, which tracked one another closely (ibrutinib vs acalabrutinib, p=0.014-0.001 from month 3 to 12) while in the unmutated patients no differences across the three BTK inhibitors were observed (p=0.08-0.74). Patients with nodal bulk >10 cm showed more prolonged treatment-related lymphocytosis, with significantly slower decline of ALC than the other nodal-bulk groups at months 9 (p=0.04) and 12 (p=0.03). Splenomegaly, in contrast, was consistently and strongly associated with faster ALC decline regardless of the cBTKi received. No differences were observed according to the presence/absence of del(17p) and/or TP53 disruption.
Conclusion: In this multicenter real-world cohort, lymphocytosis kinetics depended on treatment arm and, independently, on splenomegaly and nodal bulk, whereas del(17p) and/or TP53 disruption did not influence the overall trajectory. Ibrutinib was associated with more prolonged lymphocytosis than acalabrutinib and zanubrutinib. ALC decline was significantly slower with ibrutinib than with acalabrutinib from months 3 through 9, whereas zanubrutinib showed an intermediate kinetic profile, differing significantly from ibrutinib only at month 9. These differences were primarily driven by patients with mutated IGHV. In this subgroup, acalabrutinib induced faster ALC decline than both ibrutinib and zanubrutinib, whereas ibrutinib and zanubrutinib showed overlapping kinetics. By contrast, no significant differences were observed among the three cBTKi in patients with unmutated IGHV. Prospective studies are warranted to validate the interaction between treatment and IGHV mutational status and to define its biological basis.